董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark A. McCamish | 男 | President, Chief Executive Officer and Director | 67 | 802.76万美元 | 未持股 | 2020-03-16 |
| Jeffrey W. Bird | -- | Director | 59 | 未披露 | 未持股 | 2020-03-16 |
| Dennis J. Henner | 男 | Director | 68 | 10.62万美元 | 未持股 | 2020-03-16 |
| Ravindra Majeti | 男 | Director | 47 | 17.87万美元 | 未持股 | 2020-03-16 |
| Irving L. Weissman | 男 | Director | 80 | 20.27万美元 | 未持股 | 2020-03-16 |
| Jeffrey W. Bird | 男 | Director | 59 | 13.17万美元 | 未持股 | 2020-03-16 |
| Ian T. Clark | 男 | Director | 59 | 11.02万美元 | 未持股 | 2020-03-16 |
| Kristine M. Ball | 女 | Director | 48 | 11.71万美元 | 未持股 | 2020-03-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark A. McCamish | 男 | President, Chief Executive Officer and Director | 67 | 802.76万美元 | 未持股 | 2020-03-16 |
| Chris H. Takimoto | 男 | Chief Medical Officer | 61 | 315.33万美元 | 未持股 | 2020-03-16 |
| Ann D. Rhoads | 女 | Chief Financial Officer | 54 | 296.02万美元 | 未持股 | 2020-03-16 |
| Craig S. Gibbs | 男 | Chief Business Officer | 57 | 54.99万美元 | 未持股 | 2020-03-16 |
董事简历
中英对照 | 中文 | 英文- Mark A. McCamish
-
MarkA.McCamish自2017年5月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。2009年7月至2017年4月，McCamish博士担任制药公司Sandoz Inc.的生物制药开发全球主管。他拥有超过25年的企业管理、临床和制药研究和学术经验。McCamish博士在加州大学圣巴巴拉分校（University of California at Santa Barbara）获得体育学士学位和人体工程学硕士学位，在宾夕法尼亚州立大学（Pennsylvania State University）获得营养科学博士学位，在加州大学洛杉矶分校（University of California at Los Angeles）获得医学博士学位。
Mark A. McCamish, has been a member of the Board since December 2019. Since November 2020 Dr McCamish has served as President, Chief Executive Officer and member of the board of directors of IconOVir Bio, Inc., a biotechnology company. From May 2017 to April 2020 Dr. McCamish served as President, Chief Executive Officer and member of the board of directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in April 2020. From July 2009 to April 2017 Dr. McCamish served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish currently serves on the board of directors of Vincerx Pharma, Inc., a publicly traded biopharmaceutical company. Dr. McCamish received both a B.A. in Physical Education and an M.A. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Nutritional Sciences from the Pennsylvania State University and an M.D. from the University of California at Los Angeles. - MarkA.McCamish自2017年5月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。2009年7月至2017年4月，McCamish博士担任制药公司Sandoz Inc.的生物制药开发全球主管。他拥有超过25年的企业管理、临床和制药研究和学术经验。McCamish博士在加州大学圣巴巴拉分校（University of California at Santa Barbara）获得体育学士学位和人体工程学硕士学位，在宾夕法尼亚州立大学（Pennsylvania State University）获得营养科学博士学位，在加州大学洛杉矶分校（University of California at Los Angeles）获得医学博士学位。
- Mark A. McCamish, has been a member of the Board since December 2019. Since November 2020 Dr McCamish has served as President, Chief Executive Officer and member of the board of directors of IconOVir Bio, Inc., a biotechnology company. From May 2017 to April 2020 Dr. McCamish served as President, Chief Executive Officer and member of the board of directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in April 2020. From July 2009 to April 2017 Dr. McCamish served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish currently serves on the board of directors of Vincerx Pharma, Inc., a publicly traded biopharmaceutical company. Dr. McCamish received both a B.A. in Physical Education and an M.A. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Nutritional Sciences from the Pennsylvania State University and an M.D. from the University of California at Los Angeles.
- Jeffrey W. Bird
-
JeffreyW.Bird自2015年6月以来一直担任我们的董事会成员。Bird自2003年7月起担任Sutter Hill Ventures（一家风险投资公司）总经理。Bird博士自2005年以来担任医疗设备公司Restoration Robotics，Inc.的董事会成员，自2003年以来担任制药公司PortolaPharmaceuticals，Inc.的董事会成员。此前，Bird博士于2008年至2017年担任Threshold Pharmaceuticals，Inc.的董事会成员，并于2011年至2014年担任Horizon Pharma，Inc.的董事会成员。Bird博士在斯坦福大学（Stanford University）获得生物科学学士学位，在斯坦福大学（Stanford University）获得癌症生物学博士学位，在斯坦福医学院（Stanford Medical School）获得医学博士学位。
Jeffrey W. Bird has served as a member of our Board of Directors since June 2015. Since July 2003 Dr. Bird has been a managing director of Sutter Hill Ventures, a venture capital firm. Dr. Bird has served as a member of the Board of Directors of Restoration Robotics, Inc., a medical device company, since 2005 and Portola Pharmaceuticals, Inc., a pharmaceutical company, since 2003. Previously, Dr. Bird served on the Board of Directors of Threshold Pharmaceuticals, Inc. from 2008 to 2017 and of Horizon Pharma, Inc. from 2011 to 2014. Dr. Bird received a B.S. in Biological Sciences from Stanford University, a Ph.D. in Cancer Biology from Stanford University and an M.D. from Stanford Medical School. - JeffreyW.Bird自2015年6月以来一直担任我们的董事会成员。Bird自2003年7月起担任Sutter Hill Ventures（一家风险投资公司）总经理。Bird博士自2005年以来担任医疗设备公司Restoration Robotics，Inc.的董事会成员，自2003年以来担任制药公司PortolaPharmaceuticals，Inc.的董事会成员。此前，Bird博士于2008年至2017年担任Threshold Pharmaceuticals，Inc.的董事会成员，并于2011年至2014年担任Horizon Pharma，Inc.的董事会成员。Bird博士在斯坦福大学（Stanford University）获得生物科学学士学位，在斯坦福大学（Stanford University）获得癌症生物学博士学位，在斯坦福医学院（Stanford Medical School）获得医学博士学位。
- Jeffrey W. Bird has served as a member of our Board of Directors since June 2015. Since July 2003 Dr. Bird has been a managing director of Sutter Hill Ventures, a venture capital firm. Dr. Bird has served as a member of the Board of Directors of Restoration Robotics, Inc., a medical device company, since 2005 and Portola Pharmaceuticals, Inc., a pharmaceutical company, since 2003. Previously, Dr. Bird served on the Board of Directors of Threshold Pharmaceuticals, Inc. from 2008 to 2017 and of Horizon Pharma, Inc. from 2011 to 2014. Dr. Bird received a B.S. in Biological Sciences from Stanford University, a Ph.D. in Cancer Biology from Stanford University and an M.D. from Stanford Medical School.
- Dennis J. Henner
-
DennisJ.Henner自2015年11月以来一直担任我们的董事会成员。他是Blackstone Life Sciences（原名Clarus Ventures，LLC）的首席科学顾问，该公司是一家风险投资公司，自2005年3月成立以来，他一直担任该公司的董事总经理。在加入Clarus之前，Henner博士是MPM Capital（一家梦百合风险投资公司）的普通合伙人。从1981年到2001年，他曾担任Genentech公司的执行官，在那里他曾担任多种职务，包括研究高级副总裁，也曾担任Genentech公司的执行委员会的成员。Henner博士曾于2012年至2015年担任制药公司AeriePharmaceuticals，Inc.的董事会成员，并于2012年至2013年担任制药公司Humanigen，Inc.的董事会成员。Henner博士在弗吉尼亚大学（University of Virginia）获得微生物学博士学位，并在斯克里普斯诊所和研究基金会（Scripps Clinic and Research Foundation）进行研究生培训。
Dennis J. Henner has served as a member of our Board of Directors since November 2015. He is the Chief Scientific Advisor of Blackstone Life Sciences, formerly Clarus Ventures, LLC, a venture capital firm, where he served as Managing Director from the firm's inception in March 2005 to January 2018. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. From 1981 to 2001 Dr. Henner was an executive at Genentech, where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee. Dr. Henner previously served as a member of the Board of Directors of Aerie Pharmaceuticals, Inc., a pharmaceutical company, from 2012 to 2015 and Humanigen, Inc., a pharmaceutical company, from 2012 to 2013. Dr. Henner received a Ph.D. in Microbiology from the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation. - DennisJ.Henner自2015年11月以来一直担任我们的董事会成员。他是Blackstone Life Sciences（原名Clarus Ventures，LLC）的首席科学顾问，该公司是一家风险投资公司，自2005年3月成立以来，他一直担任该公司的董事总经理。在加入Clarus之前，Henner博士是MPM Capital（一家梦百合风险投资公司）的普通合伙人。从1981年到2001年，他曾担任Genentech公司的执行官，在那里他曾担任多种职务，包括研究高级副总裁，也曾担任Genentech公司的执行委员会的成员。Henner博士曾于2012年至2015年担任制药公司AeriePharmaceuticals，Inc.的董事会成员，并于2012年至2013年担任制药公司Humanigen，Inc.的董事会成员。Henner博士在弗吉尼亚大学（University of Virginia）获得微生物学博士学位，并在斯克里普斯诊所和研究基金会（Scripps Clinic and Research Foundation）进行研究生培训。
- Dennis J. Henner has served as a member of our Board of Directors since November 2015. He is the Chief Scientific Advisor of Blackstone Life Sciences, formerly Clarus Ventures, LLC, a venture capital firm, where he served as Managing Director from the firm's inception in March 2005 to January 2018. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. From 1981 to 2001 Dr. Henner was an executive at Genentech, where he held various positions including Senior Vice President of Research, and was a member of Genentech's executive committee. Dr. Henner previously served as a member of the Board of Directors of Aerie Pharmaceuticals, Inc., a pharmaceutical company, from 2012 to 2015 and Humanigen, Inc., a pharmaceutical company, from 2012 to 2013. Dr. Henner received a Ph.D. in Microbiology from the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
- Ravindra Majeti
-
Ravindra Majeti自2020年8月起担任万春医药公司的董事会成员。Majeti博士与他人共同创立了Forty Seven, Inc.，自2015年5月起担任Forty Seven, Inc.董事会成员。Majeti博士在斯坦福大学担任多个职位，包括自2018年9月起担任血液学系医学系教授、血液学系主任；2015年11月起任血液科医学系副教授，2009年至2015年11月任血液科医学系助理教授。他在哈佛大学（Harvard University）获得生化科学学士学位，在加州大学旧金山分校（University of California，San Francisco）获得博士学位和医学博士学位，并在布莱根妇女医院（Brigham and Women’s Hospital）完成内科住院医师学位。Majeti博士在斯坦福大学（Stanford University）完成了血液学研究。
Ravindra Majeti has served on our board since August, 2020. Dr. Majeti co-founded Forty Seven, Inc. and has served as a member of its board of directors since May 2015. Dr. Majeti served in various positions at Stanford University, including as a Professor in the Department of Medicine, Division of Hematology, Chief of the Division of Hematology since September 2018 as an Associate Professor in the Department of Medicine, Division of Hematology, since November 2015 and as an Assistant Professor in the Department of Medicine, Division of Hematology, from 2009 to November 2015. He received an A.B. in Biochemical Sciences from Harvard University, a Ph.D. and an M.D. from the University of California, San Francisco and completed a residency in internal medicine at Brigham and Women's Hospital. Dr. Majeti completed a Fellowship in Hematology at Stanford University. - Ravindra Majeti自2020年8月起担任万春医药公司的董事会成员。Majeti博士与他人共同创立了Forty Seven, Inc.，自2015年5月起担任Forty Seven, Inc.董事会成员。Majeti博士在斯坦福大学担任多个职位，包括自2018年9月起担任血液学系医学系教授、血液学系主任；2015年11月起任血液科医学系副教授，2009年至2015年11月任血液科医学系助理教授。他在哈佛大学（Harvard University）获得生化科学学士学位，在加州大学旧金山分校（University of California，San Francisco）获得博士学位和医学博士学位，并在布莱根妇女医院（Brigham and Women’s Hospital）完成内科住院医师学位。Majeti博士在斯坦福大学（Stanford University）完成了血液学研究。
- Ravindra Majeti has served on our board since August, 2020. Dr. Majeti co-founded Forty Seven, Inc. and has served as a member of its board of directors since May 2015. Dr. Majeti served in various positions at Stanford University, including as a Professor in the Department of Medicine, Division of Hematology, Chief of the Division of Hematology since September 2018 as an Associate Professor in the Department of Medicine, Division of Hematology, since November 2015 and as an Assistant Professor in the Department of Medicine, Division of Hematology, from 2009 to November 2015. He received an A.B. in Biochemical Sciences from Harvard University, a Ph.D. and an M.D. from the University of California, San Francisco and completed a residency in internal medicine at Brigham and Women's Hospital. Dr. Majeti completed a Fellowship in Hematology at Stanford University.
- Irving L. Weissman
-
IrvingL.Weissman，共同创立了我们的公司，并自2015年5月起担任我们的董事会成员。Weissman博士从2003年开始担任斯坦福干细胞生物学与再生医学研究所（Stanford Institute for Stem Cell Biology and Regenerative Medicine）的主任，以及斯坦福路德维希癌症干细胞研究中心（Stanford Ludwig Center for Cancer Stem Cell Research）的主任。Weissman博士曾是生物技术公司Amgen和生物技术公司T Cell Sciences，Inc.的创始科学顾问委员会成员。他此前也曾担任StemCells，Inc.（于2016年被Microbot Medical Ltd.（制药公司）收购）的董事会成员（从1997年到2016年）。他在Systemix，Inc.（一家生物技术公司）、StemCells，Inc.（一家生物技术公司）和Cellerant Therapeutics，Inc.（一家生物技术公司）联合创立、担任董事并担任科学顾问委员会主席。Weissman博士是美国国家科学院（National Academy of Sciences）、美国国家医学科学院（National Academy of Medicine）和美国艺术与科学协会（American Association of Arts and Sciences）的成员。他在Montana State University获得B.S.，在Stanford University School of Medicine获得M.D.。他拥有几个荣誉博士学位。
Irving L. Weissman, co-founded our company and has served as a member of our Board of Directors since May 2015. Since 2003 Dr. Weissman has served as the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Dr. Weissman was a member of the founding Scientific Advisory Boards of Amgen, a biotechnology company, and T Cell Sciences, Inc., a biotechnology company. He also previously served as a member of the Board of Directors of StemCells, Inc., acquired by Microbot Medical Ltd. in 2016 a pharmaceutical company, from 1997 to 2016. He co-founded, served as a Director, and chaired the Scientific Advisory Board at SyStemix, Inc., a biotechnology company, StemCells, Inc., a biotechnology company, and Cellerant Therapeutics, Inc., a biotechnology company. Dr. Weissman is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Association of Arts and Sciences. He received a B.S. from Montana State University and an M.D. from Stanford University School of Medicine. He has several honorary Ph.D.s. - IrvingL.Weissman，共同创立了我们的公司，并自2015年5月起担任我们的董事会成员。Weissman博士从2003年开始担任斯坦福干细胞生物学与再生医学研究所（Stanford Institute for Stem Cell Biology and Regenerative Medicine）的主任，以及斯坦福路德维希癌症干细胞研究中心（Stanford Ludwig Center for Cancer Stem Cell Research）的主任。Weissman博士曾是生物技术公司Amgen和生物技术公司T Cell Sciences，Inc.的创始科学顾问委员会成员。他此前也曾担任StemCells，Inc.（于2016年被Microbot Medical Ltd.（制药公司）收购）的董事会成员（从1997年到2016年）。他在Systemix，Inc.（一家生物技术公司）、StemCells，Inc.（一家生物技术公司）和Cellerant Therapeutics，Inc.（一家生物技术公司）联合创立、担任董事并担任科学顾问委员会主席。Weissman博士是美国国家科学院（National Academy of Sciences）、美国国家医学科学院（National Academy of Medicine）和美国艺术与科学协会（American Association of Arts and Sciences）的成员。他在Montana State University获得B.S.，在Stanford University School of Medicine获得M.D.。他拥有几个荣誉博士学位。
- Irving L. Weissman, co-founded our company and has served as a member of our Board of Directors since May 2015. Since 2003 Dr. Weissman has served as the Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine and Director of the Stanford Ludwig Center for Cancer Stem Cell Research. Dr. Weissman was a member of the founding Scientific Advisory Boards of Amgen, a biotechnology company, and T Cell Sciences, Inc., a biotechnology company. He also previously served as a member of the Board of Directors of StemCells, Inc., acquired by Microbot Medical Ltd. in 2016 a pharmaceutical company, from 1997 to 2016. He co-founded, served as a Director, and chaired the Scientific Advisory Board at SyStemix, Inc., a biotechnology company, StemCells, Inc., a biotechnology company, and Cellerant Therapeutics, Inc., a biotechnology company. Dr. Weissman is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Association of Arts and Sciences. He received a B.S. from Montana State University and an M.D. from Stanford University School of Medicine. He has several honorary Ph.D.s.
- Jeffrey W. Bird
-
Jeffrey W. Bird, M.D., Ph.D.，2008年11月以来，他担任Threshold Pharmaceuticals, Inc.的董事会成员。他是Sutter Hill Ventures（位于加州帕罗奥图的风险资本公司）的董事总经理。他曾担任Gilead Sciences的业务运营高级副总裁负责业务发展和商业活动。他还担任斯坦福大学（Stanford ）生物科学学位（1982年）和斯坦福大学（Stanford ）医学院的癌症生物学博士学位（1988年）和硕士学位（1992年）。他目前是Horizon Pharma, Inc.（上市公司）、Portola Pharmaceuticals, Inc.（上市公司）和一些私人生物技术公司的董事会成员。
Jeffrey W. Bird has served as a member of our board of directors since November 2008. Dr. Bird is a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982 a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of Portola Pharmaceuticals, Inc., a public company, and a number of private biotechnology companies. Dr. Bird was formerly a board member of Horizon Pharma, Inc., a public company. - Jeffrey W. Bird, M.D., Ph.D.，2008年11月以来，他担任Threshold Pharmaceuticals, Inc.的董事会成员。他是Sutter Hill Ventures（位于加州帕罗奥图的风险资本公司）的董事总经理。他曾担任Gilead Sciences的业务运营高级副总裁负责业务发展和商业活动。他还担任斯坦福大学（Stanford ）生物科学学位（1982年）和斯坦福大学（Stanford ）医学院的癌症生物学博士学位（1988年）和硕士学位（1992年）。他目前是Horizon Pharma, Inc.（上市公司）、Portola Pharmaceuticals, Inc.（上市公司）和一些私人生物技术公司的董事会成员。
- Jeffrey W. Bird has served as a member of our board of directors since November 2008. Dr. Bird is a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982 a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of Portola Pharmaceuticals, Inc., a public company, and a number of private biotechnology companies. Dr. Bird was formerly a board member of Horizon Pharma, Inc., a public company.
- Ian T. Clark
-
Ian T. Clark，曾担任Corvus Pharmaceuticals， Inc.的成员。自2017年1月起担任董事会成员。Clark先生在生物技术和制药行业拥有超过35年的经验，最近担任Genentech的首席执行官和董事会成员，直到他于2016年12月退休。在他担任首席执行官的7年任期内，Clark先生和他的团队向市场推出了11种新药，用于治疗类风湿性关节炎、特发性肺纤维化和各种类型的癌症。Clark先生被Glassdoor评为最高评级的首席执行官之一，被旧金山商业时报评为湾区最受尊敬的首席执行官，并被Heath Business Woman's Association授予年度荣誉导师。在加入Genentech之前，Clark先生在美国、英国、加拿大、东欧和法国的诺华（Novartis）、赛诺菲（Sanofi）、伊瓦克斯（Ivax）和塞尔（Searle）担任各种职务，责任越来越大。目前，他是几家上市生物制药和生物技术公司的董事会成员：Takeda Pharmaceutical Company Limited、Guardant Health， Inc.、Olema Oncology和Kyverna Therapeutics， Inc.。Clark先生曾任职于Forty - Seven Inc.、Shire Pharmaceuticals, Inc.、Kite Pharma, Inc.、Agios Pharmaceuticals, Inc.和Avrobio， Inc.的董事会。他也是生物技术行业协会的董事会成员，联邦储备第12区经济顾问委员会成员，以及格拉德斯通研究所的BioFulcrum董事会成员。Clark先生在英国Southampton大学获得生物科学学士学位和荣誉科学博士学位。
Ian T. Clark,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2017. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in December 2016. During his seven-year tenure as CEO, Mr. Clark and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Mr. Clark was among the highest rated CEOs by Glassdoor, recognized as the Bay Area's most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association. Prior to joining Genentech, Mr. Clark held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited, Guardant Health, Inc., Olema Oncology and Kyverna Therapeutics, Inc. Mr. Clark previously served on the Boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., Agios Pharmaceuticals, Inc. and Avrobio, Inc. He was also on the Board of Biotechnology Industry Association, on the Economic Advisory Council of the 12th District of the Federal Reserve and on the BioFulcrum Board of the Gladstone Institute. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom. - Ian T. Clark，曾担任Corvus Pharmaceuticals， Inc.的成员。自2017年1月起担任董事会成员。Clark先生在生物技术和制药行业拥有超过35年的经验，最近担任Genentech的首席执行官和董事会成员，直到他于2016年12月退休。在他担任首席执行官的7年任期内，Clark先生和他的团队向市场推出了11种新药，用于治疗类风湿性关节炎、特发性肺纤维化和各种类型的癌症。Clark先生被Glassdoor评为最高评级的首席执行官之一，被旧金山商业时报评为湾区最受尊敬的首席执行官，并被Heath Business Woman's Association授予年度荣誉导师。在加入Genentech之前，Clark先生在美国、英国、加拿大、东欧和法国的诺华（Novartis）、赛诺菲（Sanofi）、伊瓦克斯（Ivax）和塞尔（Searle）担任各种职务，责任越来越大。目前，他是几家上市生物制药和生物技术公司的董事会成员：Takeda Pharmaceutical Company Limited、Guardant Health， Inc.、Olema Oncology和Kyverna Therapeutics， Inc.。Clark先生曾任职于Forty - Seven Inc.、Shire Pharmaceuticals, Inc.、Kite Pharma, Inc.、Agios Pharmaceuticals, Inc.和Avrobio， Inc.的董事会。他也是生物技术行业协会的董事会成员，联邦储备第12区经济顾问委员会成员，以及格拉德斯通研究所的BioFulcrum董事会成员。Clark先生在英国Southampton大学获得生物科学学士学位和荣誉科学博士学位。
- Ian T. Clark,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2017. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in December 2016. During his seven-year tenure as CEO, Mr. Clark and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Mr. Clark was among the highest rated CEOs by Glassdoor, recognized as the Bay Area's most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association. Prior to joining Genentech, Mr. Clark held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited, Guardant Health, Inc., Olema Oncology and Kyverna Therapeutics, Inc. Mr. Clark previously served on the Boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., Agios Pharmaceuticals, Inc. and Avrobio, Inc. He was also on the Board of Biotechnology Industry Association, on the Economic Advisory Council of the 12th District of the Federal Reserve and on the BioFulcrum Board of the Gladstone Institute. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
- Kristine M. Ball
-
Kristine M. Ball ，她曾一直担任我们的首席财务官和高级副总裁（2012年11月以来）。任职Relypsa公司之前，她曾担任独立顾问（从2011年6月到2012年10月），负责为生命科学初创公司提供各种战略和操作业务事项的建议。成为顾问之前，她曾担任KAI Pharmaceuticals公司（被Amgen公司收购，药物发现公司）的金融和管理的高级副总裁和首席财务官（从2005年2月到2011年1月），负责财务、管理和战略规划，参与风险资本融资，制药合作，以及作为KAI公司收购的顾问。任职KAI公司之前，她曾担任Exelixis公司（生物技术公司）的财务副总裁（从2000年到2005年），负责4次收购、首次公开发行（ipo）和其它融资。任职Exelixis公司之前，她曾担任安永会计师事务所（Ernst & Young）的生命科学领域的审计实践的高级经理。她持有Babson College的会计学士学位，也拥有会计师资格证。
Kristine M. Ball has served as a member of our Board of Directors since February 2018. From September 2017 to March 2020 she has served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a publicly listed biopharmaceutical company acquired by Foamix Pharmaceuticals Ltd. From November 2012 to October 2016 Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a publicly listed pharmaceutical company acquired by Galenica. From June 2011 to October 2012 Ms. Ball was an independent consultant advising start up life science companies on various strategic and operational business matters. From 2005 to 2011 Ms. Ball served as Senior Vice President of Finance and Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc. acquired by Amgen, a drug discovery company. From 2000 to 2005 Ms. Ball served as Vice President of Finance at Exelixis, Inc., a biotechnology company. Prior to Exelixis, Ms. Ball was a senior manager in Ernst & Young's life sciences audit practice. Ms. Ball received a B.S. from Babson College. - Kristine M. Ball ，她曾一直担任我们的首席财务官和高级副总裁（2012年11月以来）。任职Relypsa公司之前，她曾担任独立顾问（从2011年6月到2012年10月），负责为生命科学初创公司提供各种战略和操作业务事项的建议。成为顾问之前，她曾担任KAI Pharmaceuticals公司（被Amgen公司收购，药物发现公司）的金融和管理的高级副总裁和首席财务官（从2005年2月到2011年1月），负责财务、管理和战略规划，参与风险资本融资，制药合作，以及作为KAI公司收购的顾问。任职KAI公司之前，她曾担任Exelixis公司（生物技术公司）的财务副总裁（从2000年到2005年），负责4次收购、首次公开发行（ipo）和其它融资。任职Exelixis公司之前，她曾担任安永会计师事务所（Ernst & Young）的生命科学领域的审计实践的高级经理。她持有Babson College的会计学士学位，也拥有会计师资格证。
- Kristine M. Ball has served as a member of our Board of Directors since February 2018. From September 2017 to March 2020 she has served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a publicly listed biopharmaceutical company acquired by Foamix Pharmaceuticals Ltd. From November 2012 to October 2016 Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a publicly listed pharmaceutical company acquired by Galenica. From June 2011 to October 2012 Ms. Ball was an independent consultant advising start up life science companies on various strategic and operational business matters. From 2005 to 2011 Ms. Ball served as Senior Vice President of Finance and Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc. acquired by Amgen, a drug discovery company. From 2000 to 2005 Ms. Ball served as Vice President of Finance at Exelixis, Inc., a biotechnology company. Prior to Exelixis, Ms. Ball was a senior manager in Ernst & Young's life sciences audit practice. Ms. Ball received a B.S. from Babson College.
高管简历
中英对照 | 中文 | 英文- Mark A. McCamish
MarkA.McCamish自2017年5月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。2009年7月至2017年4月，McCamish博士担任制药公司Sandoz Inc.的生物制药开发全球主管。他拥有超过25年的企业管理、临床和制药研究和学术经验。McCamish博士在加州大学圣巴巴拉分校（University of California at Santa Barbara）获得体育学士学位和人体工程学硕士学位，在宾夕法尼亚州立大学（Pennsylvania State University）获得营养科学博士学位，在加州大学洛杉矶分校（University of California at Los Angeles）获得医学博士学位。
Mark A. McCamish, has been a member of the Board since December 2019. Since November 2020 Dr McCamish has served as President, Chief Executive Officer and member of the board of directors of IconOVir Bio, Inc., a biotechnology company. From May 2017 to April 2020 Dr. McCamish served as President, Chief Executive Officer and member of the board of directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in April 2020. From July 2009 to April 2017 Dr. McCamish served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish currently serves on the board of directors of Vincerx Pharma, Inc., a publicly traded biopharmaceutical company. Dr. McCamish received both a B.A. in Physical Education and an M.A. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Nutritional Sciences from the Pennsylvania State University and an M.D. from the University of California at Los Angeles.- MarkA.McCamish自2017年5月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。2009年7月至2017年4月，McCamish博士担任制药公司Sandoz Inc.的生物制药开发全球主管。他拥有超过25年的企业管理、临床和制药研究和学术经验。McCamish博士在加州大学圣巴巴拉分校（University of California at Santa Barbara）获得体育学士学位和人体工程学硕士学位，在宾夕法尼亚州立大学（Pennsylvania State University）获得营养科学博士学位，在加州大学洛杉矶分校（University of California at Los Angeles）获得医学博士学位。
- Mark A. McCamish, has been a member of the Board since December 2019. Since November 2020 Dr McCamish has served as President, Chief Executive Officer and member of the board of directors of IconOVir Bio, Inc., a biotechnology company. From May 2017 to April 2020 Dr. McCamish served as President, Chief Executive Officer and member of the board of directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in April 2020. From July 2009 to April 2017 Dr. McCamish served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish currently serves on the board of directors of Vincerx Pharma, Inc., a publicly traded biopharmaceutical company. Dr. McCamish received both a B.A. in Physical Education and an M.A. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Nutritional Sciences from the Pennsylvania State University and an M.D. from the University of California at Los Angeles.
- Chris H. Takimoto
ChrisH.Takimoto自2016年2月起担任我们的首席医疗官。2010年9月至2016年1月，Takimoto博士担任制药公司Janssen研究与开发，LLC肿瘤治疗领域实验医学早期开发的Vice President。2008年至2010年，Takimoto博士担任制药公司Ortho Biotech Oncology研究与开发转化医学高级主管。他在行业和学术界拥有超过30年的经验。Takimoto博士在斯坦福大学（Stanford University）获得化学学士学位，在耶鲁大学（Yale University）获得药理学博士学位，在耶鲁大学医学院（Yale University School of Medicine）获得医学博士学位。
Chris H. Takimoto has served as our Chief Medical Officer since February 2016. From September 2010 to January 2016 Dr. Takimoto served as Vice President of Experimental Medicine Early Development in the Oncology Therapeutic area for Janssen Research and Development, LLC, a pharmaceutical company. From 2008 to 2010 Dr. Takimoto served as Senior Director of Translational Medicine of Ortho Biotech Oncology Research and Development, a pharmaceutical company. He has over thirty years of experience in the industry and academia. Dr. Takimoto received a B.S. in Chemistry from Stanford University, a Ph.D. in Pharmacology from Yale University and an M.D. from Yale University School of Medicine.- ChrisH.Takimoto自2016年2月起担任我们的首席医疗官。2010年9月至2016年1月，Takimoto博士担任制药公司Janssen研究与开发，LLC肿瘤治疗领域实验医学早期开发的Vice President。2008年至2010年，Takimoto博士担任制药公司Ortho Biotech Oncology研究与开发转化医学高级主管。他在行业和学术界拥有超过30年的经验。Takimoto博士在斯坦福大学（Stanford University）获得化学学士学位，在耶鲁大学（Yale University）获得药理学博士学位，在耶鲁大学医学院（Yale University School of Medicine）获得医学博士学位。
- Chris H. Takimoto has served as our Chief Medical Officer since February 2016. From September 2010 to January 2016 Dr. Takimoto served as Vice President of Experimental Medicine Early Development in the Oncology Therapeutic area for Janssen Research and Development, LLC, a pharmaceutical company. From 2008 to 2010 Dr. Takimoto served as Senior Director of Translational Medicine of Ortho Biotech Oncology Research and Development, a pharmaceutical company. He has over thirty years of experience in the industry and academia. Dr. Takimoto received a B.S. in Chemistry from Stanford University, a Ph.D. in Pharmacology from Yale University and an M.D. from Yale University School of Medicine.
- Ann D. Rhoads
Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
Ann D. Rhoads,most recently served as Chief Financial Officer of Forty Seven, Inc., a publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc., a publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Graduate School of Business Administration.- Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
- Ann D. Rhoads,most recently served as Chief Financial Officer of Forty Seven, Inc., a publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was Executive Vice President and Chief Financial Officer of Zogenix, Inc., a publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Graduate School of Business Administration.
- Craig S. Gibbs
- 暂无中文简介
Craig S. Gibbs has served as our Chief Business Officer since September 2015. Dr. Gibbs was an independent consultant from April 2013 to September 2015. From April 2014 to September 2016 Dr. Gibbs served as a Scientific Advisor to Tobira Pharmaceuticals and also served as a Member of the Board of Directors from April 2014 to March 2015. From June 1992 to April 2013 Dr. Gibbs served in various positions at Gilead, including as Vice President of Commercial Strategy/Planning and Operations from 2007 to 2013 and as Senior Director, Corporate Development from 2004 to 2007 Senior Director, Biology Research from 1998 to 2004 and in other research and development positions from 1992 to 1998. Prior to his time at Gilead, Dr. Gibbs served from 1989 to 1992 as Visiting Post-doctoral Scientist at Genentech. Dr. Gibbs has also served as a member of the Board of Directors of Aridis Pharmaceuticals since April 2015. Dr. Gibbs received a B.S. in Biochemistry from Massey University, an M.B.A. from Golden Gate University and a Ph.D. in Molecular Biology from the University of Glasgow. - 暂无中文简介
- Craig S. Gibbs has served as our Chief Business Officer since September 2015. Dr. Gibbs was an independent consultant from April 2013 to September 2015. From April 2014 to September 2016 Dr. Gibbs served as a Scientific Advisor to Tobira Pharmaceuticals and also served as a Member of the Board of Directors from April 2014 to March 2015. From June 1992 to April 2013 Dr. Gibbs served in various positions at Gilead, including as Vice President of Commercial Strategy/Planning and Operations from 2007 to 2013 and as Senior Director, Corporate Development from 2004 to 2007 Senior Director, Biology Research from 1998 to 2004 and in other research and development positions from 1992 to 1998. Prior to his time at Gilead, Dr. Gibbs served from 1989 to 1992 as Visiting Post-doctoral Scientist at Genentech. Dr. Gibbs has also served as a member of the Board of Directors of Aridis Pharmaceuticals since April 2015. Dr. Gibbs received a B.S. in Biochemistry from Massey University, an M.B.A. from Golden Gate University and a Ph.D. in Molecular Biology from the University of Glasgow.